SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
ARIAD Pharmaceuticals
An SI Board Since September 1996
Posts SubjectMarks Bans Symbol
4474 134 0 ARIA
Emcee:  jaybe Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
4124This compares the IBB to Ariad: finance.yahoo.com{"allowChartStacking"tktom-2/3/2016
4123Another day of following the IBB in lockstep with almost identical charts. No wVidpok1-2/3/2016
4122Today we witnessed the IBB down about 35 percent from its recent high last summeVidpok1-2/2/2016
4121Thank you, Peter.tom pope-2/2/2016
4120MDVN is one of the stocks that looks very cheap to me. I could easily see them bBiomaven-2/2/2016
4119>>'788 is targeting two mutations, EGFR and HER2, driven by exon 20 inBiomaven-2/2/2016
4118OT, i.e. not Aria/ Peter, you used to follow MDVN, I think. Do you still?I Ittom pope-2/2/2016
4117BR, good to see you here.trading_cyclist-2/2/2016
4116Biomaven, I like to look at outcomes as probabilities. AP32788 is an investigattktom-2/2/2016
4115Thanks Biomaven for confirming that a very good Phase 1 for 788 might be sufficiVidpok1-2/2/2016
4114Great to see you hear TC. Hope all the great posters from Ihub join us to makeVidpok1-2/2/2016
4113>> Would phase 1 & 2 trials suffice the requirements for approval for Biomaven-2/2/2016
4112With all the trials that Ariad is trying to fund for Iclusig, Iclusig second lintktom-2/1/2016
4111Would you agree that a successful phase one study would be enough to "move tktom-2/1/2016
4110Would phase 1 & 2 trials suffice the requirements for approval for an unmet tktom-2/1/2016
4109Cancelled iHub subscription. Good to be here, and look forward to learning from trading_cyclist-2/1/2016
4108Perhaps Denner intends to allow 788 sufficient time to establish safety and effiVidpok1-2/1/2016
4107Would you agree that a successful phase one study would be enough to "moveVidpok1-2/1/2016
4106Would phase 1 & 2 trials suffice the requirements for approval for an unmet jesspro-2/1/2016
4105I completely agree.trading_cyclist-2/1/2016
4104>>For the purposes of establishing a buyout price 788 should have a substaBiomaven22/1/2016
4103TC although 788 is years away from profitability, as Jaybe said there is likelyVidpok1-2/1/2016
4102Sun launches generic Gleevec in US market, pursuant to prior settlement with NVSDewDiligence_on_SI-2/1/2016
4101Reasonably conservative patient population given for '788... Based on 6,000jaybe32/1/2016
4100Excellent Still can't wait for elaboration. As well as brig data. GLTA (PuraVida)-2/1/2016
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News